NFATC2 and hepatocellular carcinoma: In patients with HCC, lnc-EGFR is highly expressed in Tregs, where it binds specifically to EGFR, prevents its ubiquitination and degradation, and maintains the downstream activation of AP-1 and NF-AT1 (two transcription factors of FOXP3), thereby enhancing the immunosuppressive function of Tregs and promoting HCC progression.358 It has been revealed that the Treg lncRNAs Flicr and Flatr, both of which are highly conserved and enriched in activated Tregs, control FOXP3 expression and the immunosuppressive function of Tregs.359,360